Organized by KHIDI USA, Korea Biohealth R&BD Night brings together researchers, biotech and health-tech innovators, industry professionals, and other stakeholders interested in Korea–U.S. R&D collaboration and commercialization.
The evening begins with the Korea R&D Investment Strategy Seminar, where TIPA (Korea Technology and Information Promotion Agency for SMEs), KEIT (Korea Planning & Evaluation Institute of Industrial Technology), and KHIDI (Korea Health Industry Development Institute) will share their 2027 R&D investment priorities and support programs. The program also features concurrent sessions in the Havana and Santo Domingo rooms: a Grant Writing Seminar focused on U.S. and Korean funding opportunities and a Biopharma Dealmaking session exploring both sides of the negotiating table.
As the first R&BD event under KHIDI USA’s expanded R&D support activities, the evening reflects our broader effort to connect researchers and institutions, facilitate funding and R&D collaboration, and bridge promising research toward industry partnerships and business development.
See you there!
Join us for an evening spotlighting the power of global collaboration in healthcare innovation. University of Tsukuba Night 2026 brings together eighteen innovative ventures in the fields of MedTech and Biotech, including university startups and pre-startup teams.
University of Tsukuba is one of Japan's leading national universities, with more than 16,000 students, a vast campus in Tsukuba Science City, and a long tradition of academic excellence dating back to 1872. In 2024, the University established its Malaysia Campus, further strengthening its commitment to international education, research, and innovation.
The participating ventures represent not only individual technological breakthroughs, but also the growth of a global startup ecosystem built upon collaborations among universities across Asia, Europe, North America, and Central Asia. This event aims to strengthen connections between the Japanese and U.S. innovation communities while fostering new partnerships among entrepreneurs, researchers, investors, and industry leaders.
The participating ventures include startups and entrepreneurial teams emerging directly from the University of Tsukuba's research pipeline, alongside ventures affiliated with partner universities worldwide, including the University of Bordeaux, National Cheng Kung University, The Ohio State University, IIT Bombay, Ruhr University Bochum, and Al-Farabi Kazakh National University.
University of Tsukuba Night 2026 is more than a startup showcase. It highlights the important role that global university partnerships play in advancing healthcare innovation and translating research into real-world impact, demonstrating how universities, research institutions, entrepreneurs, investors, and innovation ecosystem partners can work together across borders to address some of the world's most pressing healthcare challenges.
View the event's poster here!
Don’t miss your chance to witness innovation, celebrate diversity, and support impact at our Demo Day. Reserve your spot today and be part of the movement towards a more inclusive and equitable future.
Join us at Venture Café for an engaging panel discussion that unpacks the realities of doing business in Saudi Arabia. Hear from experienced practitioners as they challenge common assumptions, share insights on the entrepreneurial landscape, and discuss emerging opportunities for founders, investors, and partners.
Whether you’re curious about the market or actively exploring the region, this is a chance to learn, ask questions, and connect. This event is hosted by the Babson Global Center for Entrepreneurial Leadership (BGCEL) whose purpose is to promote the entrepreneurial ecosystem of Saudi Arabia, and is part of a bootcamp for Saudi founders to scale their businesses hosted at Babson College.
This event is sponsored by the Babson Global Center for Entrepreneurial Leadership and CIC.
Connecting Korean Innovation with Boston’s Global Startup & Investment Ecosystem
Join leading investors, founders, biotech experts, and innovators from Korea and Boston for an evening of cross-border collaboration, startup networking, and global innovation exchange. Hosted as part of Venture Café Cambridge Thursday Gathering, this special program is designed to connect promising Korean deep tech and biotech startups with Boston’s world-class startup, investment, and research ecosystem.
The event will feature VC-led panel discussions on biotech exits, cross-border investment strategies, founder experiences, AI innovation showcases, startup networking, and interactive Skillthon presentations. Participants will have opportunities to engage directly with venture capitalists, entrepreneurs, biotech leaders, and innovation ecosystem experts from both Korea and the Greater Boston area.
Co-organized by: Consulate General of the Republic of Korea in Boston, Korea Health Industry Development Institute (KHIDI), Korea Technology and Information Promotion Agency for SMEs (TIPA), Korea Evaluation Institute of Industrial Technology (KEIT), and Seoul National University Hospital.
Featured Korean Startups & Companies
Portrai: Portrai is an AI-powered spatial biology company developing next-generation drug discovery platforms through spatial transcriptomics and advanced data analytics. The company integrates AI with spatial biology to uncover new therapeutic insights and accelerate precision medicine innovation.
Space LiinTech: Space LiinTech is a pioneering space biopharma company building microgravity-based drug research platforms for in-orbit pharmaceutical R&D. By combining biotechnology and space infrastructure, the company is expanding new frontiers for drug discovery and space medicine innovation.
PROTEINA: PROTEINA is a leading biotech company specializing in single-molecule protein interaction analysis for precision therapeutics and AI-driven drug discovery. Its proprietary SPID platform enables ultra-high-resolution protein-protein interaction analysis to support next-generation antibody and biomarker development.
Txinno Bioscience: Txinno Bioscience is a biotech company developing small molecule and TPD to treat cancers. Txinno’s flagship pipeline, TXN10128 (ENPP1 inhibitor, Ph1), has demonstrated clinical PoC as the combo partner for chemo/ADC as the essential immune remodeler that improves DoR. Txinno has also advanced its preclinical pipeline, TXN12923, the first ULK1 PROTAC that suppresses autophagy-mediated
resistance to RAS-targeted treatments.
MedimabBio: MedimabBio is a biotech startup developing innovative antibody-based therapeutics and precision medicine solutions targeting unmet medical needs. The company focuses on advancing novel biologics and translational research to improve patient outcomes in complex diseases.
Elisigen: Elisigen is a biotechnology company developing advanced AAV gene therapies with a strong focus on ophthalmology and neurology. Utilizing proprietary technologies like the Helper-in-One (HIO) platform, the company is translating innovative pipelines into transformative treatments for unmet medical needs.
